Modified live marker vaccine candidate CP7_E2alf provides early onset of protection against lethal challenge infection with classical swine fever virus after both intramuscular and oral immunization

• Published in: Vaccine 2009-11, Vol.27 (47), p.6522-6529
• Main Authors: Leifer, Immanuel, Lange, Elke, Reimann, Ilona, Blome, Sandra, Juanola, Sandra, Duran, Joan Plana, Beer, Martin
• Format: Article
• Language: English
• Subjects: Administration, Oral; Allergy and Immunology; Animals; Antibodies, Viral - blood; Applied microbiology; Biological and medical sciences; Body temperature; C-strain vaccine; Candidate marker vaccine CP7_E2alf; Cell Line; Classical Swine Fever - immunology; Classical Swine Fever - prevention & control; Classical swine fever virus; Classical swine fever virus (CSFV); Classical swine fever virus - genetics; Classical swine fever virus - immunology; Emergency vaccination; Experiments; Fever; Fundamental and applied biological sciences. Psychology; Good Manufacturing Practice; Hogs; Immunization; Infections; Injections, Intramuscular; Manufacturers; Manufacturing; Microbiology; Miscellaneous; Mutation; Outbreaks; Pestivirus; Proteins; RNA, Viral - genetics; Sequence Analysis, RNA; Swine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral Vaccines - immunology; Virology; Viruses
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2009.08.057

Abstract Due to the vast economic consequences of classical swine fever (CSF) outbreaks, emergency vaccination plans are under discussion in European Union Member States. However, animals vaccinated with the conventional C-strain vaccine are subject to trade restrictions. To ease these restrictions, potent marker vaccines are required. One promising candidate is the chimeric pestivirus CP7_E2alf. For emergency vaccination in a CSF outbreak scenario, early onset of immunity is required. Here, the studies performed with a CP7_E2alf virus stock produced under good manufacturing conditions (GMP) are reported. In challenge experiments, CP7_E2alf induced full clinical protection 1 week after intramuscular vaccination, and 2 weeks after oral immunization. Furthermore, even after application of diluted vaccine preparations complete protection could be achieved if challenge infection was carried out 4 weeks after vaccination. In conclusion, GMP-produced CP7_E2alf proved to be a suitable marker vaccine candidate – also for emergency vaccination – both after intramuscular and oral application.